Jpmorgan Chase & CO Ngm Biopharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Dec 26, 2024	BUY	$1.17 - $1.92 $21,645 - $35,520	18,500 New	18,500 $29,000
Q1 2024 May 10, 2024	SELL	$1.17 - $1.92 $11,408 - $18,721	-9,751 Reduced 34.52%	18,500 $29,000
Q4 2023 Dec 26, 2024	BUY	$0.6 - $1.31 $16,950 - $37,008	28,251 New	28,251 $24,000
Q4 2023 Feb 12, 2024	SELL	$0.6 - $1.31 $831,495 - $1.82 Million	-1,385,825 Reduced 98.0%	28,251 $24,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $910,558 - $2.92 Million	867,199 Added 158.57%	1,414,076 $1.51 Million
Q2 2023 Aug 11, 2023	BUY	$2.44 - $4.53 $17,116 - $31,777	7,015 Added 1.3%	546,877 $1.42 Million
Q1 2023 May 18, 2023	BUY	$3.72 - $5.4 $115,212 - $167,243	30,971 Added 6.09%	539,862 $2.2 Million
Q1 2023 May 11, 2023	SELL	$3.72 - $5.4 $214,450 - $311,299	-57,648 Reduced 10.18%	508,891 $2.08 Million
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $111,309 - $422,061	32,642 Added 6.11%	566,539 $2.85 Million
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $234,727 - $329,439	-18,644 Reduced 3.37%	533,897 $6.98 Million
Q2 2022 Aug 11, 2022	BUY	$10.58 - $17.5 $196,999 - $325,850	18,620 Added 3.49%	552,541 $7.08 Million
Q1 2022 May 11, 2022	SELL	$13.81 - $18.6 $1.22 Million - $1.65 Million	-88,617 Reduced 14.23%	533,921 $8.14 Million
Q4 2021 Feb 10, 2022	SELL	$17.26 - $22.02 $79,050 - $100,851	-4,580 Reduced 0.73%	622,538 $11 Million
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $12.6 Million - $16.4 Million	627,118 New	627,118 $13.2 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.